General Information
Drug ID
DR00309
Drug Name
Saquinavir
Synonyms
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; Fortovase; Fortovase (TN); Fortovase(TM); Invirase; Invirase (TN); Invirase(TM)(monomesylate); QNC-ASN-HPH-DIQ-NTB; ROC; Ro 31-8959; Ro 318959; Ro-31-8959; SQV; Saguinavir; Saquinavir (JAN/USP/INN)
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD11: 1C62.Z] Approved [1]
Therapeutic Class
Anti-HIV Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=441243"></iframe>
3D MOL 2D MOL
Formula
C38H50N6O5
Canonical SMILES
CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O
InChI
InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1
InChIKey
QWAXKHKRTORLEM-UGJKXSETSA-N
CAS Number
CAS 127779-20-8
Pharmaceutical Properties Molecular Weight 670.855 Topological Polar Surface Area 167
Heavy Atom Count 49 Rotatable Bond Count 13
Hydrogen Bond Donor Count 5 Hydrogen Bond Acceptor Count 7
PubChem CID
441243
PubChem SID
10298771 , 103179606 , 104624996 , 104829254 , 11467142 , 11468262 , 11486850 , 117695825 , 14790389 , 14912870 , 24424137 , 24424140 , 24424146 , 24424150 , 26706895 , 36885127 , 46392170 , 46394116 , 46394117 , 47720800 , 47869868 , 48169598 , 48243608 , 49666064 , 49699303 , 49743129 , 49743137 , 49746604 , 50070617 , 50105601 , 53790242 , 56320473 , 57403600 , 596481 , 74519778 , 7847495 , 7890157 , 7890295 , 7980558 , 8030420 , 830611 , 838962 , 85177047 , 85788913 , 92715215 , 93166481 , 93167028 , 93617413 , 93617549 , 99453891
ChEBI ID
CHEBI:63621
TTD Drug ID
D0WI3T
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
OATP1A2 Transporter Info Organic anion transporting polypeptide 1A2 Substrate [5]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [6]
P-GP Transporter Info P-glycoprotein 1 Substrate [7]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OATP1A2 Transporter Info Km = 36.4 microM Oocytes-OATP1A2 [5]
P-GP Transporter Info Km = 15.4 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [7]
P-GP Transporter Info Km = 14.5 microM LLC-PK1 cells-MDR1 [8]
References
1 Saquinavir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem. 2010 Dec;115(6):1495-507.
3 Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62.
4 Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44.
5 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
6 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
7 Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.
8 MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS. 2005 Oct 14;19(15):1617-25.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.